Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05355272 · ClinicalTrials.gov registry record · Phase 2
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
A Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05355272: Recruiting Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency, sponsored by Baylor College of Medicine.
NCT05355272 is a Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 20 participants, below the 132-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05355272, a Phase 2 study of Gulf War Syndrome and Adult Growth Hormone Deficiency, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency? 2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness? To determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.
Primary Outcome
The primary outcome measure is the difference of truncal fat mass percentage from baseline to six months. Truncal fat mass will be assessed at baseline, 3-months, and 6-months using calibrated dual energy x-ray absorptiometry (DEXA). A large mean difference corresponds with greater changes in truncal fat mass. Decreased truncal fat mass is associated with reduced risk of cardiovascular disease.
Conditions Studied
Interventions
- DRUG Recombinant human growth hormone
Study Locations (2)
Texas
- Michael E. DeBakey VA Medical Center - Houston
Washington
- VA Puget Sound Healthcare System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT05355272 shows while recruiting
NCT05355272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 132-participant average among 8 other Gulf War Syndrome trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Gulf War Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Recombinant human growth hormone is the first listed.
NCT05355272 reports a single indexed study location in Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT05355272 about?
NCT05355272 is a clinical study titled "Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)". The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat i...
What is the current status of trial NCT05355272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-03-11. Estimated completion is 2026-07.
What conditions does trial NCT05355272 study?
This clinical trial studies the following conditions: Gulf War Syndrome, Adult Growth Hormone Deficiency.
What interventions are being tested in trial NCT05355272?
The interventions under investigation include: Recombinant human growth hormone (DRUG).
Who is sponsoring clinical trial NCT05355272?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05355272 being conducted?
This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05355272's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Gulf War Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gulf War Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Evaluation of Montelukast in Veterans With Gulf War Illness
RECRUITING · Phase 1
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
Coenzyme Q10 for Gulf War Illness: A Replication Study
RECRUITING · Phase 3
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness
RECRUITING · NA
-
GWICTIC: NAC Mechanistic Study in Gulf War Veterans
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI